Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Sarepta Therapeutics has received a consensus recommendation of "Hold" from analysts, with six ratings for sell, fourteen for hold, and nine for buy.
• The average 1-year target price set by analysts for Sarepta is $39.32, highlighting potential upside in share value.
• In their most recent quarterly earnings, Sarepta reported an EPS of $2.02, significantly exceeding analysts' expectations of $0.89 and showing a 68.4% year-over-year revenue increase.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has earned a consensus rating of "Hold" from the twenty-nine ratings firms that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a sell rating, fourteen have given a hold rating and nine have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $39.32.

SRPT has been the topic of a number of research analyst reports. Leerink Partners raised their price target on Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a "market perform" rating in a research report on Tuesday, September 9th. Sanford C. Bernstein started coverage on Sarepta Therapeutics in a research report on Tuesday, July 29th. They issued a "market perform" rating and a $13.00 target price on the stock. Robert W. Baird lifted their target price on Sarepta Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Needham & Company LLC reissued an "underperform" rating on shares of Sarepta Therapeutics in a research report on Monday, July 28th. Finally, Scotiabank raised Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 target price on the stock in a research report on Friday, June 6th.

Sarepta Therapeutics Trading Up 15.7%

NASDAQ SRPT opened at $22.35 on Friday. The firm has a market cap of $2.18 billion, a P/E ratio of -25.69 and a beta of 0.51. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The stock's 50-day moving average is $18.17 and its 200-day moving average is $33.18. Sarepta Therapeutics has a one year low of $10.41 and a one year high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $1.13. The company had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.Sarepta Therapeutics's revenue was up 68.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC raised its position in Sarepta Therapeutics by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 4,699 shares of the biotechnology company's stock valued at $571,000 after buying an additional 218 shares during the last quarter. UMB Bank n.a. grew its stake in Sarepta Therapeutics by 53.0% in the first quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock valued at $51,000 after purchasing an additional 276 shares in the last quarter. State of Alaska Department of Revenue grew its stake in Sarepta Therapeutics by 2.6% in the first quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company's stock valued at $713,000 after purchasing an additional 285 shares in the last quarter. State of Michigan Retirement System grew its stake in Sarepta Therapeutics by 1.3% in the first quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company's stock valued at $1,461,000 after purchasing an additional 300 shares in the last quarter. Finally, Louisiana State Employees Retirement System grew its stake in Sarepta Therapeutics by 1.1% in the first quarter. Louisiana State Employees Retirement System now owns 26,800 shares of the biotechnology company's stock valued at $1,710,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.